Palbociclib for MF reducing fibrosis and more

[EPguy]

I found this subject inspired by a dead post in the Sjogren's forum.

"The drug, palbociclib, may be able to prevent the scarring of bone marrow that existing treatments (Rux etc) for myelofibrosis cannot."

medicalxpress.com/news/2021...

and active to MPL also:

" In this study, we investigated the efficacy of CDK4/6 inhibitor palbociclib alone or in combination with ruxolitinib in Jak2V617F and MPLW515L murine models of myelofibrosis. Treatment with palbociclib alone significantly reduced leukocytosis and splenomegaly and inhibited bone marrow fibrosis in Jak2V617F and MPLW515L mouse models of myelofibrosis

pubmed.ncbi.nlm.nih.gov/341...

--

and another author's wording

"“We demonstrate that CDK4/6 inhibitor palbociclib (Ibrance) in combination with ruxolitinib (Jakafi) markedly inhibits myelofibrosis, suggesting this drug combination could be an effective therapeutic strategy against this devastating blood disorder,” "

managedhealthcareexecutive....

--

I can find only the mouse study. Seems quite worthy of some clinical work. Why haven't we heard about it? Or have we?

Note that Ibrance (palbociclib) is FDA approved for another cancer so is theoretically could be avail for MF pts in greatest need. But this would be experimental.

[Mishie14]

very exciting news! This could turn out to be the best news so far for treating MF. Hoping this drug becomes available. Thank you for sharing.

[DougyW]

Now just need a specialist to get funding to extend the trial. 🤞

[EPguy in reply to DougyW]

I think the catch is the drugs are from competitors. Incyte for Rux, Pfizer for Ibrance. So it's messy business-wise. As you say it might need to be an academic source.

If I were an MF pt out of options I would ask my Dr about this off label therapy. My POV is biased, having a different evil condition with no decent options.

[ciye]

That's good news,

[Sprout23]

Memorial Sloan Kettering Cancer Center has clinical trial for Rux with Abemaciclib (also CDK inh) for MF patients.

[EPguy in reply to Sprout23]

Good info. I see both are part of a new class.

"Abemaciclib is the third CDK 4/6 inhibitor arriving to the market after palbociclib and ribociclib"

pubmed.ncbi.nlm.nih.gov/330...

Here is the NCT page: clinicaltrials.gov/study/NC...

Only 18 pts, New York area. must have failed Rux.

--

So we'll have a clue soon. It's phase 1 so this is indeed a quite new approach.